EU FMD vs US DSCSA vs Russia’s Chestny ZNAK: 7 Key Differences Pharma Exporters Must Know

Exporting pharmaceuticals to the EU, US, or Russia? Compare EU FMD, US DSCSA, and Chestny ZNAK across 7 critical differences — from code structure to reporting — before you build your Track & Trace strategy.

If your packaging line ships to more than one of these three markets, you already know that “serialization” doesn’t mean the same thing everywhere. The European Union, the United States, and Russia each built their own national traceability system to fight counterfeit medicines — and while they share a common ancestor in the 2D Data Matrix code, the way each system verifies, reports, and enforces compliance is fundamentally different.

Treating all three as one project is one of the most common (and expensive) mistakes exporters make. Below are the seven differences that actually change how your packaging line, your software stack, and your compliance team need to operate.

1. How Do EU FMD, US DSCSA, and Chestny ZNAK Verify Pharmaceutical Products?

The EU’s Falsified Medicines Directive (FMD) uses a point-of-dispense verification model. A unique identifier is checked once, at the pharmacy counter, against the European Medicines Verification System (EMVS). What happens to the pack between the factory and the pharmacy isn’t tracked step by step.

The US DSCSA takes a transaction-based interoperability approach. Instead of one central database, trading partners exchange Transaction Information, Transaction History, and a Transaction Statement (T3) as product changes hands, with real-time authentication increasingly handled through the Verification Router Service (VRS).

Russia’s Chestny ZNAK goes further than both. It requires continuous chain-of-custody reporting — every single change of ownership, from manufacturer to distributor to pharmacy to final sale, is logged with the Center for Research in Perspective Technologies (CRPT). Nothing moves through the Russian supply chain without the system knowing.

2. How Do EU FMD, US DSCSA, and Chestny ZNAK Handle Data and Reporting? 

EU FMD relies on the European Medicines Verification Organisation (EMVO) and a centralized EU hub connected to national verification systems in each member state — a shared, federated model governed collectively by industry stakeholders.

DSCSA, by contrast, has no single central repository. It’s built on interoperable networks between manufacturers, wholesalers, and dispensers, with the FDA setting the rules but not operating a central database itself.

Chestny ZNAK is run by a single state-linked operator, CRPT, which issues the codes, receives every reporting event, and holds the authoritative national record. This centralization gives Russian authorities far more granular, real-time visibility than either the EU or US model.

3. What Information Is Encoded in Each Pharmaceutical 2D Data Matrix? 

All three systems use a GS1-compliant 2D Data Matrix carrying a GTIN, serial number, batch/lot number, and expiry date. But Chestny ZNAK adds two elements the other two don’t require: a 4-digit verification key and a cryptographic “crypto-tail” of up to 88 numerical digits, generated by CRPT itself. This crypto code can only be obtained through an active, verified connection to CRPT’s OMS system — meaning a Russian-compliant line needs a live data connection just to print a legal code, not just to report after the fact.

4. Which Pharmaceutical Products Are Covered by EU FMD, DSCSA, and Chestny ZNAK? 

EU FMD and US DSCSA both focus primarily on prescription pharmaceuticals, with OTC products largely outside scope (with narrow exceptions under discussion in the EU). Chestny ZNAK is far broader — it mandates labeling, scanning, and reporting for both prescription and over-the-counter medicines, and pharmaceuticals sit alongside eleven other regulated product categories in the same national system, from tobacco to tires. Exporters who assume their OTC lines are exempt in Russia the way they might be in Brussels or Washington are setting themselves up for a compliance gap.

5. What Are the Aggregation Requirements Under EU FMD, DSCSA, and Chestny ZNAK? 

Aggregation — linking individual unit codes to their case and pallet-level parent codes — is optional or still-maturing under EU FMD and applied unevenly across US trading partners under DSCSA, depending on the specific agreement between parties.

Under Chestny ZNAK, aggregation is mandatory and enforced hierarchically. Every case and pallet needs its own aggregated code linking every unit inside it, and any change to a batch — partial shipments, returns, breakdowns — must be reported as it happens. This is one of the most resource-intensive parts of Russian compliance for manufacturers used to the lighter aggregation demands of the EU or US.

6. How Do EU FMD, DSCSA, and Chestny ZNAK Differ in Enforcement? 

DSCSA enforcement has ramped up in stages through 2025 and 2026, with the FDA issuing warning letters and civil penalties that can reach into the hundreds of thousands of dollars per violation for intentional non-compliance. EU FMD enforcement is handled at the member-state level and generally centers on blocking non-compliant packs from being dispensed rather than criminal prosecution.

Chestny ZNAK carries the steepest downside of the three. Non-compliance can mean exclusion from the Russian pharmaceutical market outright, administrative fines that scale sharply with the value of unmarked goods, and — for large-scale or deliberate violations — criminal liability under Russian law, including potential imprisonment for responsible individuals.

7. How Do Vendor Support and Market Stability Affect Serialization Compliance? 

This is the difference exporters most often overlook until it’s too late. EU FMD and DSCSA operate in stable, well-established vendor ecosystems with dozens of established serialization and reporting partners actively supporting the market.

Russia is a different story. Since 2022, a number of Western European track & trace vendors have exited the Russian market — some with formal notice, many without. Manufacturers who built their Chestny ZNAK compliance around those vendors have been left with functioning hardware but no software support, while CRPT’s MDLP reporting obligations and version updates continue regardless. Any serialization partner you choose for the Russian market needs a genuine, active local support presence — not just historical compliance credentials.

What These Serialization Differences Mean for Your Packaging Line 

The technical differences above aren’t just paperwork — they translate directly into how your line needs to be built:

• For the EU, your priority is clean, print-quality-verified codes and a reliable connection into the national verification system your product routes through.
• For the US, your priority is trading-partner interoperability — your L3/L4 systems need to exchange transaction data cleanly with every partner in your chain.
• For Russia, your priority is a live, resilient connection to CRPT’s OMS, robust aggregation handling at every packaging level, and a support partner who is still actually present in the market.

A single Vision Inspection and track & trace platform that can flex across all three regulatory models — rather than three separate bolt-on systems — is what keeps a multi-market packaging line from turning into three compliance projects running in parallel.

Multi-Market Pharmaceutical Serialization With Jekson Vision

Jekson Vision’s REETRAK serialization platform and REESOURCE L4/L5 traceability system are built to handle exactly this kind of multi-market complexity, including full CRPT OMS integration and MDLP compliance for manufacturers navigating the Russian market alongside EU FMD and US DSCSA requirements. Talk to our team about auditing your current line for multi-market compliance.